RecruitingPhase 2NCT06658899
A Phase 2 Study of CRD-4730 in CPVT
Studying Catecholaminergic polymorphic ventricular tachycardia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cardurion Pharmaceuticals, Inc.
- Intervention
- CRD-4730(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2025 – 2027
Study locations (9)
- Cardurion Investigative Site, San Francisco, California, United States
- Cardurion Investigative Site, Morrisville, North Carolina, United States
- Cardurion Investigative Site, Houston, Texas, United States
- Cardurion Investigative Site, Madison, Wisconsin, United States
- Cardurion Investigative Site, Vancouver, British Columbia, Canada
- Cardurion Investigative Site, Saint-Herblain, France
- Cardurion Investigative Site, Pavia, Pavia, Italy
- Cardurion Investigative Site, Amsterdam, North Holland, Netherlands
- Cardurion Investigative Site, Esplugues de Llobregat, Barcelona, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06658899 on ClinicalTrials.govOther trials for Catecholaminergic polymorphic ventricular tachycardia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07148089A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Solid Biosciences Inc.
- RECRUITINGPHASE2NCT07263139Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Agiana Pharmaceuticals
- RECRUITINGNCT06661278Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited ArrhythmiasRoyal Brompton & Harefield NHS Foundation Trust
See all trials for Catecholaminergic polymorphic ventricular tachycardia →